BUDGET IMPACT ANALYSIS OF THE INCORPORATION OF GOLIMUMAB AS AN ADDITIONAL TREATMENT OPTION FOR PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

被引：0
|
作者：
Scaccabarozzi, L. [1 ]
Asano, E. [1 ]
Guimaraes, T. B. [1 ]
机构：
[1] Janssen, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1038
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY20
引用
收藏
页码：A244 / A244
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT OF CONCOR® AM VERSUS BISOPROLOL PLUS AMLODIPINE IN SYSTEMIC ARTERIAL HYPERTENSION TREATMENT, FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM
    Fujii, R. K.
    Restrepo, M.
    Fernandes, R. A.
    Haas, L.
    Pepe, C.
    Junqueira, M.
    VALUE IN HEALTH, 2015, 18 (03) : A138 - A138
  • [42] Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
    Wahono, Cesarius Singgih
    Hamijoyo, Laniyati
    Hendrawan, Yuriawati
    Rakinaturia, Liyana
    Mittal, Neha
    Khanna, Prabal
    Jain, Minal
    Isbagio, Harry
    PHARMACOECONOMICS-OPEN, 2023, 7 (04) : 605 - 615
  • [43] Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
    Cesarius Singgih Wahono
    Laniyati Hamijoyo
    Yuriawati Hendrawan
    Liyana Rakinaturia
    Neha Mittal
    Prabal Khanna
    Minal Jain
    Harry Isbagio
    PharmacoEconomics - Open, 2023, 7 : 605 - 615
  • [44] Budget impact analysis of the percutaneous septal occluder for treatment of ostium secundum atrial septal defects in the Brazilian Unified National Health System
    Simoes e Senna, Katia Marie
    Sarti, Flavia Mori
    Santos da Costa, Marcia Gisele
    Nita, Marcelo Eidi
    Santos, Marisa da Silva
    Tura, Bernardo Rangel
    Correia, Marcelo Goulart
    CADERNOS DE SAUDE PUBLICA, 2015, 31 (08): : 1756 - 1764
  • [45] ESTIMATING THE BUDGET IMPACT OF INTRODUCING INDACATEROL IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) FROM THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS) PERSPECTIVE
    Suzuki, C.
    Silva, N. L.
    VALUE IN HEALTH, 2011, 14 (07) : A489 - A490
  • [46] BUDGET IMPACT ANALYSIS (BIA) OF RUXOLITINIB FOR TREATMENT OF INTERMEDIATE-2 OR HIGH RISK IPSS MYELOFIBROSIS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)
    Nonino, A.
    Kim, H.
    Flora, A. P. A. D. S.
    VALUE IN HEALTH, 2021, 24 : S35 - S36
  • [47] DIABETIC MACULAR EDEMA, BUDGET IMPACT ANALYSIS FROM THE PERSPECTIVE OF THE ALGERIAN PUBLIC HEALTH SYSTEM
    Chachoua, A.
    VALUE IN HEALTH, 2016, 19 (07) : A565 - A565
  • [48] ESTIMATING THE POTENTIAL BUDGET IMPACT OF ZELBORAF (VEMURAFENIB) FOR ADVANCED MELANOMA TREATMENT IN BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Tsuchiya, C. T.
    Buschinelli, C. T.
    Maximo, M. F. M.
    Tobaruella, F. S.
    Borges, L. G.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [49] MEDICATION TREATMENT PATTERNS FOR MULTIPLE SCLEROSIS PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
    Takemoto, M. M. S.
    Takemoto, M. L.
    Fernandes, R. A.
    Duarte, G. G. F.
    Moretti, A. I. P.
    Santos, P. M. L.
    Tolentino, A. C. M.
    VALUE IN HEALTH, 2011, 14 (03) : A212 - A213
  • [50] BUDGET IMPACT ANALYSIS OF INCORPORATING CRYOBALLON CRYOABLATION FOR TREATMENT OF ATRIAL FIBRILLATION IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Borghossian, S.
    Fujii, F. A.
    Moretti, P.
    VALUE IN HEALTH, 2020, 23 : S98 - S98
12345